Novel antimalarial agent against asexual stages of P. falciparum

Novel potent Plasmodium lactate transporter PfFNT

Novel MEP pathway-targeting antimalarial agent

Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones

Novel Inhibitor of Plasmodium falciparum

Novel antischistosomal agent against chronic S. mansoni infection

Novel antischistosomal agent against chronic S. mansoni infection

Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones

Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites

Novel antimalarial agent against Plasmodium falciparum

Novel antimalarial agent, targeting P. falciparum farnesyltransferase PfFT, showing remarkable growth inhibition with EC50 value of 0.4 µM and presenting good selectivity index (SI > 250)

Selective allosteric inhibitor of Plasmodium Kinesin-5

Novel potent inhibitor of P. falciparum asexual blood stages, inhibiting heme detoxification

Novel potent broad antiparasitic agent against intracellular Leishmania amastigotes, Trypanosoma brucei, and Plasmodium falciparum

First-in-class acetyl-CoA synthetase (AcAS) inhibitor, showong single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocking P. falciparum transmission to Anopheles mosquitoes

Novel anticancer agent, inducing apoptosis, inhibiting migration and invasion

Novel highly potent and selective MNK1/2 kinases inhibitor

Potent and selective Mnk2 inhibitor

Cell-permeable superoxide dismutase (SOD) mimetic

Novel inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity

Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis.

Natural antioxidant and antidiabetic agent

Novel iminosugar, downregulatiing the interferon γ receptor by dengue virus

Natural potent antioxidant agent

Natural analogue of (-)-gambogic acid acting as a potent inhibitor of global predominant MRSA USA300

Potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors

Natural antibacterial, antileishmanial, and antifungal agent

Potent and Specific PDE10A inhibitor

Novel mixed kappa-delta opioid receptor agonist with anti-cocaine properties and reduced side-effects in rats

Novel potent and selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor

Novel anti-cancer agent, being more potent and safer than conventional indomethacin

Novel selective class IIb histone deacetylase inhibitor (HDACi), dose-dependently decreasing the viability of Acanthamoeba trophozoites

Potent and selective COX-2 inhibitor

Specific estrogen receptor α (ERα) antagonist

Novel main protease (Mpro) inhibitor, inhibiting MHV-A29, HCoV-229E, FOPV replication, and SARS-CoV-2 viral cell entry

Novel Mps1 Kinase Inhibitor

Novel inhibitor of MPS1

Novel tubulin polymerization inhibitor

Novel Dual HDAC6 and Tubulin Inhibitor, Displaying Anti-tumor Ability in Human Cancer Cells

Novel mitochondrial permeability transition pore (mPTP) inhibitor

Novel potent and selective antagonist of GluN2A-containing NMDA receptors

Novel highly potent and selective 5-HT2C agonist

Novel, potent inducer of apoptosis via the MAP kinase pathways. Inhibitor of several kinases including the tyrosine kinase FLT3-ITD

Novel inhibitor of the main protease (Mpro) of SARS-CoV-2

Novel positive allosteric modulator (PAM) of mas-related G protein-coupled receptor X1 (MRGPRX1), reducing behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential in treating neuropathic pain

Activator of MrgX1 receptor signaling

Novel peripheral CB1R antagonist, being highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation

Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors

Novel potent RORγT inhibitor

Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors

Novel selective and reproducible inhibitor of DNA synthesis in E. coli JL553

Selective enhancer of the ATP effects at fast desensitizing P2X (P2X1 and P2X3) receptors

Potent P2Y14 receptor agonist

Selective P2Y6 agonist

Selective P2Y2 agonist

Potent P2Y6 agonist

Potent and selective P2Y6 receptor agonist

Novel highly potent human CD73 inhibitor (K i = 0.673 nM)

Novel potent antagonist of P2Y 14 receptor (P2Y 14 R) (IC 50 ~20 nM at hP2Y 14 R/mP2Y 14 R)

Novel potent P2Y14 Receptor Antagonist (IC 50 , 15 nM)

Bitopic fluorescent antagonist of the A2A adenosine receptor

Novel highly selective A1 adenosine receptor (A1AR) agonist

Novel Partial Agonist of Human and Mouse A3 Adenosine Receptors (Ki = 10.9/17.8 nM, at human/mouse A3AR)

Novel highly potent A3 adenosine receptor (A3AR) antagonist with Kd values (nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat)

Potent inhibitor of TANK-binding kinase-1 (TBK1)/IKKepislon kinases

Novel inhibitor of Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor

Novel, selective, orally bioavailable, negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5)

Inhibitor of DNA damage repair

Novel inhibitor of DNA damage repair

Novel inhibitor of Human p53 and CREB Binding Protein (CREBBP) interaction

Novel potent and selective SETD8 inhibitor

Mitochondrial tRNA-specific modification, regulating efficient mitochondrial translation and energy metabolism in mammals

Novel potent tankyrase (TNKS) inhibitor (EC 50 : 2 nM)

Novel inhibitor of SLC16A3

Novel potent and selective PI3Kδ inhibitor

Potent TRPV1 agonist

Novel potent broad-spectrum metallo-β-lactamase (MβL) inhibitor, inhibiting the MβLs NDM-1, VIM-2, ImiS, and L1

Novel BBB permeable potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes

Novel antituberculosis agent. targeting the respiratory chain of Mycobacterium tuberculosis (Mtb) and being effective against multi drug resistant (MDR) Mtb

Novel minimized theta-defensin, being highly effective against CRE pathogens K. pneumoniae and E. coli in vivo, significantly enhancing survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restorin

Novel resveratrol-based multitarget-directed ligand, cellularly activating the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibiting both hMAO-B and QR2 (IC 50 s = 8.05 and 0.57 μM), and promoting hippocampal neurogenesis

Selective antagonist of melanocortin-4 receptor (MC4R)

Novel Mithramycin A (MTM) 2'-oxime (MTMox) conjugate, displaying an 11-fold increase in plasma exposure and improved efficacy in an Ewing sarcoma xenograft

Novel, potent, and selective brain-penetrant ATP-competitive mTOR inhibitor

Novel potent dual inhibitor of mTOR and HDAC1

Novel selective inhibitor of mTORC1, yielding potent inhibition of glucose uptake

Novel selective mTORC1 inhibitor, directly targeting class I glucose transporters

Novel mTOR inhibitor, exhibiting potent anticancer activities against four tumor cell lines, including MCF-7, HeLa, MGC-803, and C6, inducing cell death via apoptosis by targeting both mTORC1 and mTORC2 within cells and arrests the cell cycle of HeLa at t

Novel mitochondria-targeted photoactivatable real-time probe, being phototriggered by either UV (one-photon) or NIR (two-photon) light to form a fluorescent coumarin product and facilitate the release of drug payload

Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors.

Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors.

Novel potent multitarget ligand

Novel potent MurA inhibitor

Novel potent and selective MCL-1 inhibitor

Novel potent mutant IDH1 R132H inhibitor

Novel potent and selective cathepsin K (Cat K) inhibitor

CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. Selective suppressor of beta amyloid (Aβ)-induced glia proinflammatory cytokine production

Novel GPR119 agonist with Anti-Diabetic Efficacy in db/db Mice

Novel mitophagy activator

Major thiol in most actinomycetes involved in mycothiol biosynthesis and mycothiol-dependent enzymes such as mycothiol-dependent formaldehyde dehydrogenase and mycothione reductase

Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max

Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max

Novel inhibitor of zinc finger DHHC domain-containing (zDHHC) enzymes

Myotoxin II fragment

Novel potent, reversible and uncompetitive inhibitor of actin-stimulated ATPase activity of myosin V

Novel inducer of apoptosis in a Myc-dependent manner, inhibiting Myc-driven transformation and disrupting MYC-Max interaction

Inhibitor of the chaperonin activity of HSP60, correlating to LONP and LRP130 aggregation

Bacterial RNA polymerase (RNAP) inhibitor

Novel potent and selective PROTAC degrader of BRD3/4

Competitive inhibitor of both SPHK1 and SPHK2

Glucokinase activator (GKA)

Novel RNA labeling probe through both metabolic and enzyme-assisted manners

Deuterium labeled m6A used in important m6A physiological pathways related studies

Alkylating agent, forming DNA adducts at the C-8 position in guanine, resulting in single strand breaks, demonstrating carcinogenic action

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity

Derivative of loline

Novel antiviral agent against the replication of influenza virus A/H3N2 subtype in Madin-Darby canine kidney (MDCK) cells

Coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage

Electron donor and cofactor for many redox enzymes including nitric oxide synthetase

Partial estrogen antagonist, inhibiting angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), inducing oxidative stress, protein kinase C and calcium signaling

Novel potent full agonist for orexin receptor

Novel highly selective antibacterial agent against Propionibacterium acnes

Mixed agonist/antagonist opioid modulator, binding with high affinity to the MOR and KOR, and having relatively low affinity for the DOR

Novel fluorescent probe for detection of endogenously produced Naph-O2˙– in living cells and tissues

Novel repeat-structure-specific DNA ligand, specifically binding slipped-CAG DNA intermediates of expansion mutations

Triple reuptake inhibitor

Novel Gut-Restricted Inhibitor of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia

Antagonist of alpha-2 adrenergic receptors and inhibitor of the neuronal uptake of norepinephrine

Inhibitor of extrinsic and intrinsic thrombin generation, inhibiting clot-bound and free (fluid-phase thrombin)

Activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4

Natural DnaE1 blocker, inducing a DNA damage response in Mycobacterium tuberculosis (Mtb) and inhibiting growth by blocking the replicative DNA polymerase, DnaE1

Potent suppressor of inducible nitric oxide synthase (iNOS; NOS II)

Novel selective NaV1.1 inhibitor, reducing visceral hypersensitivity

Novel selective blocker of NaV1.7 with little affinity for NaV 1.2, 1.3, or 1.6, being more potent at human vs guinea pig NaV1.7

Potent and selective blocker of voltage-gated Nav1.7 sodium channels

Potent NaV1.7 blocker, being 5-10 fold more potent than NaV 1.2 and NaV 1.6

Novel CXC chemokine receptor 2 (CXCR2) antagonist

Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist

Potent and selective A1 adenosine receptor antagonist

Biological Active Reagents

L-Tyrosine caged with photosensitive ortho-nitrobenzyl side chain

Novel HIV-1 entry inhibitor

Novel HIV-1 entry inhibitor

Novel CD4-mimetic HIV-1 entry inhibitor

Potent agonist of the human 5-HT2A and 5-HT2C receptors

Potent and selective 5-HT2A receptor agonist

Novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy

M. tuberculosis Dihydrofolate Reductase Inhibitor

Novel inhibitor of methionine aminopeptidase 2 (MetAP2)

First-in-class, potent, and selective Lactate dehydrogenase inhibitor

First-in-class, potent, and selective Lactate dehydrogenase inhibitor

Less active trans-isomer of NCB-0846, acting as the negative control for NCB-0846, showing 13-fold weaker TNIK enzyme-inhibitory activity

Potent pan KDM Inhibitor, inhibiting KDM2A, KDM7A, KDM7B, KDM4A, KDM4C, and KDM5A

Novel inhibitor of ovarian cancer metastasis, adhesion, invasion and proliferation

Novel Agonist for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions

The first small-molecule inverse agonist for the thyroid-stimulating hormone receptor (TSHR)

TSHR neutral antagonist, inhibiting stimulated signaling but not basal signaling

Novel allosteric Eya2 phosphatase inhibitor, specifically targeting migration, invadopodia formation, and invasion of lung cancer cells

Novel AMA1-RON2 Inhibitor

Novel potent inhibitor of IRAK1/4 and FLT3

Novel SIRT1 inhibitor, inducing cell death in adult T-cell leukaemia cells

Novel GPR139 receptor agonist

Analogue of γ-hydroxybutyric acid (GHB), acting as a substrate for both the monocarboxylate transporter subtype 1 (MCT1) and subtype 4 (MCT4)

Beclin 1 mimetic, selectively binding to Bcl-xL and inducing autophagy, showing potent cytotoxicity in PC-3, PC-3a and DU145 prostate cancer cells

Novel blocker of the interaction between FGF1 and FGFRD2 to inhibit cell proliferation, showing potent antiproliferent with less cytotoxicity.

Novel NO-donor, suppressing inflammatory and nociceptive responses

Novel HMG-CoA reductase inhibitor and nitric oxide donor

Cyanogen Bromide adduct of (R)-SCH-12679, a D1 antagonist

Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects

Novel degrader of steroid receptor co-activator 1 (SRC-1)

Novel potent and highly specific IRAK4 inhibitor

Selective water-soluble gelatinase inhibitor

Potent and selective inhibitor for gelatinases, matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MPP9)

Inhibitor of Phosphodiesterase (PDE)-2

Precursor for radiolabeled diltiazem

Major metabolite of loperamide, also used as the precusor for radiolabelled loperamide

Novel G4-DNA ligand, promoting transcription in Gram-positive bacteria and repressing transcription in Gram-negatives

Novel Inhibitor of New Delhi Metallo-β-lactamase-1 (NDM-1)

Negative control compound for Necrostatin-1 related assays

Novel necroptosis inhibitor

Novel inhibitor of caspase-independent cell death with necrotic morphol, distinctly different from apoptosis, autophagy, and necroptosis, displaying strong mitochondrial reactive oxygen species and ONOO- scavenging activity

Non-narcotic analgesic for the relief of acute and chronic pain

Novel Inhibitor of DNA Glycosylases, inhibiting NEIL1 activity

Novel ATP-competitive inhibitor of Nek2 and Nek7

Natural inhibitor of tumor metastasis by upregulating the RNA-binding-protein MBNL2, inducing cell cycle arrest through multiple signaling pathways including RNA binding protein CELF6

Inhibitor of the formation of

Potent natural anti-tumor agent against metastatic colorectal cancer, resulting in cell cycle arrest at the G2/M phase and inducing apoptosis through the dysfunction of mitochondria to trigger intrinsic apoptotic pathway by untargeted metabolomic method,

Natural inducer of autophagy and apoptosis, inhibiting glutamate overexcitation and upregulation of the Wnt/β-catenin signaling pathway

Novel AR inhibitor, being selective for the testosterone stimulated AR-dependent prostate cancer cell

The first potent NAD-driven small molecular inhibitor of TcGAPDH (Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase)

Novel non-peptidic, non-covalent cruzain inhibitor

Human B-type natriuretic peptide, facilitating cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldosterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation

Anti-inflammatory, antibronchospastic agent

Novel dual Rho Kinase and norepinephrine transporter (ROCK/NET) inhibitor

Novel fluorescent RXR antagonist

Lidocaine metabolite, showing antinociceptive effects, inhibiting GlyT1-mediated glycine uptake

Modulator of the T1007 site, resulting in rapid activation of this transporter and potentiating KCC2 activity

Ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth

Novel potent Trypanosoma brucei Inhibitor

Novel inhibitor of the growth of protozoan parasites, against T. brucei bloodstream proliferation